The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Acceleron Pharma Inc. | COM | 00434H108 | 10,387 | 244,756 | SH | SOLE | 244,756 | 0 | 0 | ||
| Aerie Pharmaceuticals, Inc. | COM | 00771V108 | 99,945 | 1,672,714 | SH | SOLE | 1,672,714 | 0 | 0 | ||
| Aimmune Therapeutics, Inc. | COM | 00900T107 | 117,248 | 3,100,146 | SH | SOLE | 3,100,146 | 0 | 0 | ||
| Alder BioPharmaceuticals, Inc. | COM | 014339105 | 11,952 | 1,043,832 | SH | SOLE | 1,043,832 | 0 | 0 | ||
| Alder BioPharmaceuticals, Inc. | COM | 014339905 | 40 | 24,000 | SH | Call | SOLE | 24,000 | 0 | 0 | |
| Denali Therapeutics Inc. | COM | 24823R105 | 3,910 | 250,000 | SH | SOLE | 250,000 | 0 | 0 | ||
| Epizyme, Inc. | COM | 29428V104 | 19,554 | 1,558,108 | SH | SOLE | 1,558,108 | 0 | 0 | ||
| Insmed Incorporated | COM | 457669307 | 16,171 | 518,645 | SH | SOLE | 518,645 | 0 | 0 | ||
| Juno Therapeutics, Inc. | COM | 48205A109 | 3,885 | 85,000 | SH | SOLE | 85,000 | 0 | 0 | ||
| Loxo Oncology, Inc. | COM | 548862101 | 1,002 | 11,900 | SH | SOLE | 11,900 | 0 | 0 | ||
| uniQure N.V. | SHS | N90064101 | 2,142 | 109,350 | SH | SOLE | 109,350 | 0 | 0 | ||